Tags

Type your tag names separated by a space and hit enter

Live attenuated influenza vaccine in children.
Semin Pediatr Infect Dis. 2006 Oct; 17(4):206-12.SP

Abstract

Live attenuated influenza vaccine (LAIV) offers a novel approach to influenza vaccination and is approved for healthy individuals 5 to 49 years of age. In placebo-controlled studies in children, LAIV was 73 to 93 percent efficacious, and protection lasted more than 12 months. In head-to-head studies in children, LAIV demonstrated a 35 to 53 percent reduction in influenza attack rates compared with injectable influenza vaccine (TIV) for matched strains. Compared with TIV, LAIV has demonstrated broader serum antibody responses, particularly against mismatched influenza A. The most common adverse events are runny nose and nasal congestion. Increased rates of asthma events were observed in young children. Additional large-scale safety and efficacy studies in young children, including a formal risk-benefit assessment, are ongoing. The results of these analyses will guide potential future use in young children.

Authors+Show Affiliations

MedImmune, Inc., Gaithersburg, MD 20878, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17055372

Citation

Ambrose, Christopher S., et al. "Live Attenuated Influenza Vaccine in Children." Seminars in Pediatric Infectious Diseases, vol. 17, no. 4, 2006, pp. 206-12.
Ambrose CS, Walker RE, Connor EM. Live attenuated influenza vaccine in children. Semin Pediatr Infect Dis. 2006;17(4):206-12.
Ambrose, C. S., Walker, R. E., & Connor, E. M. (2006). Live attenuated influenza vaccine in children. Seminars in Pediatric Infectious Diseases, 17(4), 206-12.
Ambrose CS, Walker RE, Connor EM. Live Attenuated Influenza Vaccine in Children. Semin Pediatr Infect Dis. 2006;17(4):206-12. PubMed PMID: 17055372.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Live attenuated influenza vaccine in children. AU - Ambrose,Christopher S, AU - Walker,Robert E, AU - Connor,Edward M, PY - 2006/10/24/pubmed PY - 2006/12/13/medline PY - 2006/10/24/entrez SP - 206 EP - 12 JF - Seminars in pediatric infectious diseases JO - Semin Pediatr Infect Dis VL - 17 IS - 4 N2 - Live attenuated influenza vaccine (LAIV) offers a novel approach to influenza vaccination and is approved for healthy individuals 5 to 49 years of age. In placebo-controlled studies in children, LAIV was 73 to 93 percent efficacious, and protection lasted more than 12 months. In head-to-head studies in children, LAIV demonstrated a 35 to 53 percent reduction in influenza attack rates compared with injectable influenza vaccine (TIV) for matched strains. Compared with TIV, LAIV has demonstrated broader serum antibody responses, particularly against mismatched influenza A. The most common adverse events are runny nose and nasal congestion. Increased rates of asthma events were observed in young children. Additional large-scale safety and efficacy studies in young children, including a formal risk-benefit assessment, are ongoing. The results of these analyses will guide potential future use in young children. SN - 1045-1870 UR - https://www.unboundmedicine.com/medline/citation/17055372/Live_attenuated_influenza_vaccine_in_children_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1045-1870(06)00068-9 DB - PRIME DP - Unbound Medicine ER -